Paul W. Blavin
Fondatore presso Mercy Bioanalytics, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Dawn R. Mattoon | M | 51 |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | 2 anni |
Joseph Sedlak | M | - |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | 6 anni |
Sonja Perkins | F | 57 |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | - |
Paul Meister | M | 71 |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | - |
Stanley Lapidus | M | 75 |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | - |
Myla Lai-Goldman | M | 66 |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 6 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Paul W. Blavin
- Contatti personali